PT - JOURNAL ARTICLE AU - Hernández-Mora, Miguel Górgolas AU - Úbeda, Alfonso Cabello AU - Pérez, Laura Prieto AU - Álvarez, Felipe Villar AU - Álvarez, Beatriz Álvarez AU - Rodríguez Nieto, María Jesús AU - Acosta, Irene Carrillo AU - Fernández Ormaechea, Itziar AU - Mohammed Al-Hayani, Aws Waleed AU - Carballosa, Pilar AU - Martínez, Silvia Calpena AU - Ezzine, Farah AU - González, Marina Castellanos AU - Naya, Alba AU - de las Heras, Marta López AU - Rodríguez Guzmán, Marcel José AU - Guijarro, Ana Cordero AU - Lavado, Antonio Broncano AU - Valcayo, Alicia Macías AU - García, Marta Martín AU - Martínez, Javier Bécares AU - Roblas, Ricardo Fernández AU - Piris Pinilla, Miguel Ángel AU - Alen, José Fortes AU - Pernaute, Olga Sánchez AU - Bueno, Fredeswinda Romero AU - Frades, Sarah Heili AU - Barba Romero, Germán Peces AU - , TI - Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late AID - 10.1101/2020.06.13.20130088 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.13.20130088 4099 - http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130088.short 4100 - http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130088.full AB - Introduction Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease.Methods We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020.Findings A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. At baseline, 114 (61%) required oxygen support with FiO2 >0.5 % and 72 (39%) ≤0.5%. Early administration of tocilizumab, when the need of oxygen support was still below FiO2 ≤0.5%, was significantly more effective than given it in advanced stages (FiO2 >0.5 %), achieving lower rates of intubation or death (13% vs 37% repectively, p<0·001).Interpretation The benefit of tocilizumab in severe SARS-Cov-2 pneumonia is only expected when it is administrated before the need of high oxygen support.Funding None.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Medical Committee Fundacion Jimenez DiazAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript.